Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.36 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.36 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31258343 | 0.78 | PIK3CD (0.41) | NAPRTSMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL13536643 | 0.76 | HDAC1 (0.42) | SMN1; SMN2RAB9AKCNQ3KCNQ2NPC1 | |
| SCHEMBL31456638 | 0.75 | KCNQ3 (0.30) | KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL30096957 | 0.74 | FDFT1 (0.41) | — | |
| SCHEMBL29849881 | 0.74 | CYP2A6 (0.34) | KCNQ3KCNQ2 | |
| SCHEMBL23832408 | 0.74 | FDFT1 (0.41) | — | |
| SCHEMBL31165568 | 0.74 | DGAT1 (0.42) | SMN1; SMN2RAB9AALDH1A1MAPTKCNQ3 | |
| SCHEMBL12091527 | 0.71 | HPGD (0.35) | — | |
| SCHEMBL31189284 | 0.70 | DGAT1 (0.36) | RAB9AALDH1A1MAPTPIK3CDDGAT1 | |
| SCHEMBL23832350 | 0.69 | KDM4E (0.42) | RAB9AALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024217439-A1 | COMPOUND AND USE THEREOF IN TREATMENT OF CHRONIC HEPATITIS B, HEPATIC FIBROSIS AND LIVER CANCER | 河北乌图药业有限公司 | 2024-10-24 | — | — | WO | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| CN-117295726-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023244788-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | NAPRT 2287/4885SMN1; SMN2 3350/4885RAB9A 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.